GLP1R and pancreatic neoplasm: After PSM, GLP-1 RA use was associated with a lower 5-year incidence of pancreatic cancer (hazard ratio (HR) 0.49, 95% confidence interval (CI) 0.30-0.80, <i>p</i> < 0.005).